Antibody data
- Antibody Data
- Antigen structure
- References [21]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [9]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-0209-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD20 Monoclonal Antibody (2H7), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The 2H7 monoclonal antibody reacts with human CD20, a 33-36 kDa transmembrane protein. CD20 is expressed by developing B cells as well as mature B cells but not plasma cells. CD20 has been detected at low levels on a small subset of mature T cells. It is suggested that CD20 plays a role in B-cell activation. Applications Reported: This 2H7 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 2H7 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 2H7
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references TRPA1 triggers hyperalgesia and inflammation after tooth bleaching.
IL-33 Alarmin and Its Active Proinflammatory Fragments Are Released in Small Intestine in Celiac Disease.
Genetic modification of primary human B cells to model high-grade lymphoma.
Relative safety of various spermatogenic stem cell purification methods for application in spermatogenic stem cell transplantation.
Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.
Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells.
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs.
Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected Children.
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.
Evidence for innate immune system activation in HIV type 1-infected elite controllers.
Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Transcriptional profiling of mRNAs and microRNAs in human bone marrow precursor B cells identifies subset- and age-specific variations.
An efficient low cost method for gene transfer to T lymphocytes.
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.
Chen C, Huang X, Zhu W, Ding C, Huang P, Li R
Scientific reports 2021 Aug 31;11(1):17418
Scientific reports 2021 Aug 31;11(1):17418
IL-33 Alarmin and Its Active Proinflammatory Fragments Are Released in Small Intestine in Celiac Disease.
Perez F, Ruera CN, Miculan E, Carasi P, Dubois-Camacho K, Garbi L, Guzman L, Hermoso MA, Chirdo FG
Frontiers in immunology 2020;11:581445
Frontiers in immunology 2020;11:581445
Genetic modification of primary human B cells to model high-grade lymphoma.
Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ
Nature communications 2019 Oct 4;10(1):4543
Nature communications 2019 Oct 4;10(1):4543
Relative safety of various spermatogenic stem cell purification methods for application in spermatogenic stem cell transplantation.
Tian J, Ma K, Pei CB, Zhang SH, Li X, Zhou Y, Yan B, Wang HY, Ma LH
Stem cell research & therapy 2019 Dec 16;10(1):382
Stem cell research & therapy 2019 Dec 16;10(1):382
Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.
Colonna L, Peterson CW, Schell JB, Carlson JM, Tkachev V, Brown M, Yu A, Reddy S, Obenza WM, Nelson V, Polacino PS, Mack H, Hu SL, Zeleski K, Hoffman M, Olvera J, Furlan SN, Zheng H, Taraseviciute A, Hunt DJ, Betz K, Lane JF, Vogel K, Hotchkiss CE, Moats C, Baldessari A, Murnane RD, English C, Astley CA, Wangari S, Agricola B, Ahrens J, Iwayama N, May A, Stensland L, Huang MW, Jerome KR, Kiem HP, Kean LS
Nature communications 2018 Oct 25;9(1):4438
Nature communications 2018 Oct 25;9(1):4438
Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells.
Zeng Y, Liu B, Rubio MT, Wang X, Ojcius DM, Tang R, Durrbach A, Ru Z, Zhou Y, Lone YC
PloS one 2017;12(4):e0173754
PloS one 2017;12(4):e0173754
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN
Nature communications 2017 Sep 19;8(1):607
Nature communications 2017 Sep 19;8(1):607
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T, Dupéré-Richer D, Will CM, Small EC, Varghese N, Patel T, Nabet B, Popovic R, Oyer J, Bulic M, Zheng Y, Huang X, Shah MY, Maji S, Riva A, Occhionorelli M, Tonon G, Kelleher N, Keats J, Licht JD
Cell reports 2017 Oct 17;21(3):628-640
Cell reports 2017 Oct 17;21(3):628-640
Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.
van Beek JJ, Gorris MA, Sköld AE, Hatipoglu I, Van Acker HH, Smits EL, de Vries IJ, Bakdash G
Oncoimmunology 2016;5(10):e1227902
Oncoimmunology 2016;5(10):e1227902
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer T, Worah K, de Haas N, Buschow SI, de Vries IJ, Figdor CG, Hato SV
Oncoimmunology 2016 Aug;5(8):e1192739
Oncoimmunology 2016 Aug;5(8):e1192739
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Mar 15;21(6):1267-72
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Mar 15;21(6):1267-72
Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs.
de Winde CM, Zuidscherwoude M, Vasaturo A, van der Schaaf A, Figdor CG, van Spriel AB
Histochemistry and cell biology 2015 Aug;144(2):133-46
Histochemistry and cell biology 2015 Aug;144(2):133-46
Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected Children.
Muema DM, Macharia GN, Hassan AS, Mwaringa SM, Fegan GW, Berkley JA, Nduati EW, Urban BC
Journal of immunology (Baltimore, Md. : 1950) 2015 Aug 1;195(3):1082-91
Journal of immunology (Baltimore, Md. : 1950) 2015 Aug 1;195(3):1082-91
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.
Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Önen NF, Kojic E, Patel P, Brooks JT, Sereti I, Baker JV, Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Investigators
The Journal of infectious diseases 2014 Nov 1;210(9):1396-406
The Journal of infectious diseases 2014 Nov 1;210(9):1396-406
Evidence for innate immune system activation in HIV type 1-infected elite controllers.
Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, Lempicki R, Migueles SA, Sereti I
The Journal of infectious diseases 2014 Mar;209(6):931-9
The Journal of infectious diseases 2014 Mar;209(6):931-9
Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.
Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, Croughs T, Beq S, Lafaye de Micheaux S, Yao MD, Ober A, Wilson EM, Natarajan V, Imamichi H, Boulassel MR, Lederman MM, Routy JP
PLoS pathogens 2014 Jan;10(1):e1003890
PLoS pathogens 2014 Jan;10(1):e1003890
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC, Choudhary P, de Cassan SC, Biswas S, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Hodgson SH, Duncan CJ, Hill AV, Draper SJ
Immunology 2014 Apr;141(4):628-44
Immunology 2014 Apr;141(4):628-44
Transcriptional profiling of mRNAs and microRNAs in human bone marrow precursor B cells identifies subset- and age-specific variations.
Jensen K, Brusletto BS, Aass HC, Olstad OK, Kierulf P, Gautvik KM
PloS one 2013;8(7):e70721
PloS one 2013;8(7):e70721
An efficient low cost method for gene transfer to T lymphocytes.
Chicaybam L, Sodre AL, Curzio BA, Bonamino MH
PloS one 2013;8(3):e60298
PloS one 2013;8(3):e60298
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.
Duvall M, Bradley N, Fiorini RN
mAbs 2011 Mar-Apr;3(2):203-8
mAbs 2011 Mar-Apr;3(2):203-8
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.
Duvall M, Bradley N, Fiorini RN
mAbs 2011 Mar-Apr;3(2):203-8
mAbs 2011 Mar-Apr;3(2):203-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD3 FITC (Product # 11-0038-42) and Mouse IgG2b K Isotype Control APC (Product # 17-4732-81) (left) or Anti-Human CD20 APC (right). Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Cell sorting of precursor B cells subsets from CD10 positively selected cells. Immunomagnetic selection and subsequent FACS were used to isolate the five populations from pediatric and adult human BM. Shown are the FACS dot plots with sorting gates to obtain CD34 + CD19 - ProB cells, CD34 + CD19 + PreBI cells, CD34 - CD19 + CD20 dim PreBII large cells, CD34 - CD19 + CD20 - PreBII small cells, and CD34 - CD19 + CD20 high IgM + Immature B cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 4 IGF-1-dependent induction of cancer stem cell markers CD20, CD133, and CD271 (NGFR) on melanoma cells. a Melanoma cells (WM3749) co-cultured with TAB cells (days 3 and 9) show high expression of CD20 ( middle and right panels ) compared with the control culture ( left panel ) as determined by FACS analysis. Melanoma cells were co-stained with anti-CD146 (MCAM, PE-conjugated) and anti-CD20 (FITC-conjugated) antibodies to distinguish them from B cells, which are CD146-negative;percentages indicate co-expression of both markers on the malignant cells. b Melanoma cells (WM3749) co-cultured with TAB cells (day 6) show high expression of CD20, CD133 and CD271 ( left panel ) compared with minimal or low expression of those markers when tumor cells are co-cultured with NB cells ( right panel ). Co-culture of melanoma cells with TAB cells did not modulate the expression of CD144 (vascular-endothelial cadherin marker) that are normally expressed by aggressive melanomas (data not shown). Induction of CD20, CD133, and CD271 was blocked when anti-IGF-1 neutralizing antibody (10 mug/ml) was used in the co-culture ( middle panel ). Anti-IL-1, anti-PDGF or anti-VEGF antibodies had no effect on CD marker expression (data not shown). Percentages indicate co-expression of CD20, CD133, or CD271on CD146 + melanoma cells. Results are representative of two independent experiments. c Melanoma cells(WM3749, WM989 and 451Lu) cultured in the presence of recombinant IGF-1 (25 ng/ml) for 5 days sh
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Long-term expansion of human germinal center B cells ex vivo. a Primary human GC B cells were transduced with the indicated oncogenes and oncogene combinations and cultured separately for up to 120 days. Graph shows calculated theoretical absolute cell numbers (+-s.e.m., n = 3). Viable cells were assessed by trypan blue exclusion. Source data are provided as a Source Data file. b Primary human GC B cells were transduced with different oncogenes and oncogene combinations and monitored by flow cytometry. Graph shows the change in cell viability assessed by scatter characteristic by flow cytometry ( +- s.e.m., n = 3). Source data are provided as a Source Data file. c Primary human GC B cells were transduced with BCL2 in combination with other transcription factors in a pooled, competitive culture. Graph shows relative abundance of transcription factors or their mutant versions over four different timepoints ( n = 3). d Primary human GC B cells were transduced with the oncogenic cocktail BCL2 and BCL6 and cultured to day 73. Representative flow cytometry analysis ( n = 3) for the expression of the GC B cell markers CD38, CD20, CD19, CD80, CD22, CD95, CXCR4, and CD86. Red histograms show GC B cells compared to primary human naive B cells (blue). e Heat map of gene expression of freshly isolated GC B cells ( n = 3), transduced GC B cells ( BCL2-BCL6, BCL2-MYC ) cultured ex vivo for 5 or 73 days ( n = 3), plasma cell line ( n = 1), naive B cells ( n = 1), and lymphoma cell li
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 IL-33 + cells in Duodenal Mucosae of active celiac patients. Representative images of immunofluorescence analysis of duodenal sections of active CD patients. IL-33 (green), nuclei (blue). Other markers in red. In some images the epithelial compartment was delimited with white dashed lines. (A). CD31 + endothelial cells expressing IL-33 (white arrows). (B) Smooth muscle actin in red and white lines delineated intestinal crypts. The white arrows point to SMA + IL-33 + cells which are located around vascular structures and crypts. (C) Some of the IL-33 + CD90 + cells are pointed by a white arrow. (D, E) CD45+IL-33+ cells in lamina propria , but not in epithelial compartment. (F) A few IL-33 + CD11c + where close to the epithelium of ACD patients. (G) Some of the CD20 + IL-33 + cells are pointed with white arrows. (H) Some of the lamina propria double positive IL-33 + CD64 + are pointed with white arrows. (I) EPCAM + IL-33 + cells are pointed with white arrows. The images were taken with 20X and 63X objectives from the SP5 Leica Microscope and objectives 20X, 40X and 60X from the Apotome Zeiss microscope.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Identification of dental pulp stem cells (DPSCs). Human DPSCs were positive for the cell surface antigens CD73, CD90, and CD105, as well as negative for CD14, CD20, CD34, and CD45 demonstrated by flow cytometry ( A ). DPSCs were cultured under osteogenic ( B , 14 days) or adipogenic ( C , 21 days) conditions, and showed mineralized nodules and lipid clusters as revealed by alizarin red and oil red staining, respectively. Scale bar = 400 ( B ) or 100 ( C ) mum.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 Allogeneic HCT in SHIV-C Infected, cART-treated RM. a Schematic of SHIV-C infection and allogeneic bone marrow transplantation strategy in SHIV-C infected, cART-treated RM. b Plasma Viral Loads (PVL) were measured longitudinally following transplant as specified in Fig. 1a . c White blood count (WBC) (x10 3 /uL). d Absolute Neutrophil Count (ANC) (x10 3 /uL). e Absolute Lymphocyte Count (ALC) (x10 3 /uL). f Platelet Count (PLT) (x10 3 /uL). g Hemoglobin (Hgb) concentration (g/dL). h Percent whole blood donor chimerism, measured by microsatellite analysis. i Percent donor myeloid (CD11b + CD3-) chimerism, measured flow cytometrically. j Percent donor CD4 + T cell (CD3+ CD4+ CD8- CD20- CD11b- lymphocytes) chimerism, measured flow cytometrically. k Percent donor CD8 + T cell (CD3+ CD8+ CD4- CD20- CD11b- lymphocytes) chimerism, measured by flow cytometry
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 Marker verification and validation of independent markers in BALL cells by immunofluorescence and flow cytometry. The expression of CD20 ( a - c ) and CD38 ( d - f ), were positive on BALL cell membranes. CD90f ( g - i ) and CD49f ( j , k ) were not expressed in BALL cells. DAPI indicates the cell nucleus. This finding was confirmed via the conducted flow cytometry analysis. Scale bar = 100 mum